Exhibit
10.1


 


SECOND
AMENDMENT TO


EMPLOYMENT
AGREEMENT


 


This
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of May 1, 2022 and amends the Employment
Agreement (defined below), between Lantern Pharma Inc. (the “Company”) and David R. Margrave (“Executive”).
The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Parties.”


 


RECITALS


 


WHEREAS,
the Company and Executive have entered into the Employment Agreement, dated as of June 16, 2020 and previously amended as of January
1, 2022 (collectively, the “Employment Agreement”), wherein the Company is employing Executive as the Company’s
Chief Financial Officer; and


 


WHEREAS,
the Company and Executive wish to amend the Employment Agreement to (i) extend the term of the Employment Agreement to July 30, 2024;
and (ii) increase the annual pre-tax base salary level for Executive under the Employment Agreement to $343,000 commencing as of May
1, 2022.


 


NOW
THEREFORE, in consideration of the mutual covenants set forth herein and other legal and valuable consideration, the Parties agree as
follows:


 


		1.	The
                                            first sentence of Section 1.4 of the Employment Agreement is hereby amended to read in its
                                            entirety as follows:



 


“The
term of Executive’s employment under this Agreement shall begin on the Effective Date and, unless sooner terminated in accordance
with Section 3, shall conclude on July 30th, 2024 (the “Term”).”


 


		2.	Section
                                            I of Exhibit A to the Employment Agreement is hereby amended to read in its entirety as follows:



 


“Base
Salary. The Company shall pay Executive an initial pre-tax base salary (“Initial Base Salary”) of $300,000.00
(Three Hundred Thousand U.S. Dollars) per annum, less all applicable withholdings, with such Initial Base Salary to be paid in accordance
with the Company’s standard payroll practices with respect to pay periods (or applicable portions thereof) during the Term of this
Agreement that occur on or after June 16, 2020 and prior to January 1, 2022. Commencing January 1, 2022, the Initial Base Salary shall
be increased to $312,000.00 (Three Hundred Twelve Thousand U.S. Dollars) per annum, less all applicable withholdings, with such increased
Initial Base Salary (“Adjusted Base Salary”) to be paid in accordance with the Company’s standard payroll
practices with respect to pay periods (or applicable portions thereof) during the Term of this Agreement that occur on or after January
1, 2022 and prior to May 1, 2022. Commencing May 1, 2022, the Adjusted Base Salary shall be increased to $343,000.00 (Three Hundred Forty-Three
Thousand U.S. Dollars) per annum, less all applicable withholdings, with such increased Adjusted Base Salary to be paid in accordance
with the Company’s standard payroll practices with respect to pay periods (or applicable portions thereof) during the Term of this
Agreement that occur on or after May 1, 2022.”


 


		3.	All
                                            other terms of and conditions to the Employment Agreement shall continue in full force and
                                            effect.



 






    	1



    	 



    

 





IN
WITNESS WHEREOF, the Parties have executed this Amendment to be effective as of May 1, 2022.


 





	 	COMPANY:


	 	 
	 	Lantern
    Pharma Inc.
	 	 	 
	 		 
	 	By:	/s/
    Panna Sharma
	 	 	Panna
    Sharma
	 	 	Chief
    Executive Officer
	 	 	 
	 	EXECUTIVE:
	 	 	 
	 	 	/s/
    David R. Margrave
	 	 	David
    R. Margrave


 






    	2